• CCS Authors Team

CCS researchers identify novel drug target and inhibitor for the treatment of Hedgehog-driven cancer

FDA approved inhibitors of oncogenic Hedgehog signaling have partially failed in clinical trials due to the development of drug resistance. These disappointing results urgently call for the identification of novel drug targets that overcome the problem of Hedgehog inhibitor resistance in human malignancies with high medical need.

The Aberger lab now reports on the identification of the kinase DYRK1B as novel target for the treatment of cancers with Hedgehog inhibitor resistance. Blocking DYRK1B function, either chemically or genetically, results in repression of oncogenic Hedgehog signaling by reducing the expression of GLI transcription factors. Further, the Aberger group together with the Munich based biotech company 4SC Discovery identified a novel DYRK1 inhibitor with therapeutic efficacy and pharmacological properties suitable for the use in future clinical trials. The results have been published in the latest edition of Oncotarget. Read the full study by Gruber et al.


Cancer Cluster Salzburg at SCRI

3rd Medical Department

Paracelsus Medical University Clinics Salzburg

Müllner Hauptstrasse 48, 5020 Salzburg, Austria


Cancer Cluster Salzburg at PLUS

Department of Biosciences

University of Salzburg

Hellbrunner Strasse 34, 5020 Salzburg, Austria